Standout Papers

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patie... 2007 2026 2013 2019 1.4k
  1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (2008)
    Craig L. Leonardi, Alexa B. Kimball et al. The Lancet
  2. Guidelines of care for the management of psoriasis and psoriatic arthritis (2008)
    Alan Menter, Alice B. Gottlieb et al. Journal of the American Academy of Dermatology
  3. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial (2007)
    Alan Menter, Stephen K. Tyring et al. Journal of the American Academy of Dermatology
  4. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis (2016)
    Kenneth B. Gordon, Andrew Blauvelt et al. New England Journal of Medicine
  5. Guidelines of care for the management of psoriasis and psoriatic arthritis (2008)
    Alice B. Gottlieb, Neil J. Korman et al. Journal of the American Academy of Dermatology
  6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial (2017)
    Kristian Reich, April W. Armstrong et al. Journal of the American Academy of Dermatology
  7. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) (2015)
    Kim Papp, Kristian Reich et al. Journal of the American Academy of Dermatology
  8. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials (2018)
    Kenneth B. Gordon, Bruce Strober et al. The Lancet
  9. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease (2012)
    Gerd R Burmester, Remo Panaccione et al. Annals of the Rheumatic Diseases
  10. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial (2022)
    Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology
  11. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (2021)
    Kenneth B. Gordon, Peter Foley et al. The Lancet
  12. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (2021)
    Kristian Reich, Kim Papp et al. The Lancet

Immediate Impact

4 by Nobel laureates 13 from Science/Nature 67 standout
Sub-graph 1 of 17

Citing Papers

Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
Psoriasis
2021 Standout

Works of Kenneth B. Gordon being referenced

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
2018 Standout
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
2008 Standout
and 4 more

Author Peers

Author Last Decade Papers Cites
Kenneth B. Gordon 13281 7428 2118 3138 198 16.0k
Richard G. Langley 14165 9354 2499 3341 255 18.4k
Craig L. Leonardi 11088 6216 1960 2559 130 13.7k
Diamant Thaçi 7915 7355 2376 3116 364 12.9k
Alan Menter 18409 11772 3205 4555 375 24.5k
Bruce Strober 7289 4868 1159 1897 276 10.6k
Kristian Reich 19466 13460 3972 4889 491 25.3k
Wolf‐­Henning Boehncke 8415 4271 1316 2658 355 12.9k
Gerald G. Krueger 7427 3515 1030 3062 119 9.6k
Neil J. Korman 5384 3856 757 2424 158 9.5k
Richard B. Warren 5953 3220 1007 1794 340 7.6k

All Works

Loading papers...

Rankless by CCL
2026